. 2022 May 6;27(5):e393-e401.

doi: 10.1093/oncolo/oyac039.

"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

Salma Shickh^{1

2}, Leslie E Oldfield³, Marc Clausen¹, Chloe Mighton^{1

2}, Agnes Sebastian^{1

2}, Alessia Calvo^{1

4}, Nancy N Baxter^{1

5

6}, Lesa Dawson^{7

8}, Lynette S Penney⁹, William Foulkes^{10

11}, Mark Basik^{10

11}, Sophie Sun^{12

13}, Kasmintan A Schrader^{12

13}, Dean A Regier^{12

13}, Aly Karsan^{12

13}, Aaron Pollett¹⁴, Trevor J Pugh^{3

15}, Raymond H Kim^{2

3

14

16}, Yvonne Bombard^{1

2

15}; CHARM Consortium

Collaborators, Affiliations

Collaborators

CHARM Consortium:
Trevor J Pugh, Raymond H Kim, Yvonne Bombard, Adriana Aguilar-Mahecha, Melyssa Aronson, Mark Basik, Nancy N Baxter, Hal Berman, Marcus Q Bernardini, Tulin Cil, Katie Compton, Lesa Dawson, Irfan Dhalla, Tiana Downs, Christine Elser, Gabrielle E V Ene, Kirsten M Farncombe, Sarah Ferguson, William Foulkes, Robert Gryfe, Michelle R Jacobson, Aly Karsan, Monika Kastner, Pardeep Kaurah, Jordan Lerner-Ellis, Stephanie Lheureux, Beatrice Luu, Shelley MacDonald, Brian Mckee, Nicole Mittmann, Kristen Mohler, Leslie Oldfield, Seema Panchal, Lynette S Penney, Carolyn Piccinin, Aaron Pollett, Dean Regier, Zoulikha Rezoug, Matthew Richardson, Anabel Scaranelo, Kasmintan A Schrader, Kara Semotiuk, Lillian Siu, Sophie Sun, Emily Thain, Gulisa Turashvili, Karin Wallace, Thomas Ward, Shelley Westergard, Wei Xu, Celeste Yu

Affiliations

¹ St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
² University of Toronto, Toronto, ON, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
⁴ McMaster University, Hamilton, ON, Canada.
⁵ Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
⁶ Department of Surgery, University of Toronto, Toronto, ON, Canada.
⁷ Memorial University, St. John's, NL, Canada.
⁸ Eastern Health Authority, St. John's, NL, Canada.
⁹ Dalhousie University, Halifax, NS, Canada.
¹⁰ McGill University, Montréal, QC, Canada.
¹¹ Jewish General Hospital, Montréal, QC, Canada.
¹² BC Cancer, Vancouver, BC, Canada.
¹³ University of British Columbia, Vancouver, BC, Canada.
¹⁴ Mount Sinai Hospital, Toronto, ON, Canada.
¹⁵ Ontario Institute for Cancer Research, Toronto, ON, Canada.
¹⁶ The Hospital for Sick Children, Toronto, ON, Canada.

PMID: 35385106
PMCID: PMC9075003
DOI: 10.1093/oncolo/oyac039

"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

Salma Shickh et al. Oncologist. 2022.

. 2022 May 6;27(5):e393-e401.

doi: 10.1093/oncolo/oyac039.

Authors

Collaborators

CHARM Consortium:
Trevor J Pugh, Raymond H Kim, Yvonne Bombard, Adriana Aguilar-Mahecha, Melyssa Aronson, Mark Basik, Nancy N Baxter, Hal Berman, Marcus Q Bernardini, Tulin Cil, Katie Compton, Lesa Dawson, Irfan Dhalla, Tiana Downs, Christine Elser, Gabrielle E V Ene, Kirsten M Farncombe, Sarah Ferguson, William Foulkes, Robert Gryfe, Michelle R Jacobson, Aly Karsan, Monika Kastner, Pardeep Kaurah, Jordan Lerner-Ellis, Stephanie Lheureux, Beatrice Luu, Shelley MacDonald, Brian Mckee, Nicole Mittmann, Kristen Mohler, Leslie Oldfield, Seema Panchal, Lynette S Penney, Carolyn Piccinin, Aaron Pollett, Dean Regier, Zoulikha Rezoug, Matthew Richardson, Anabel Scaranelo, Kasmintan A Schrader, Kara Semotiuk, Lillian Siu, Sophie Sun, Emily Thain, Gulisa Turashvili, Karin Wallace, Thomas Ward, Shelley Westergard, Wei Xu, Celeste Yu

Affiliations

¹ St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada.
² University of Toronto, Toronto, ON, Canada.
³ Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
⁴ McMaster University, Hamilton, ON, Canada.
⁵ Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia.
⁶ Department of Surgery, University of Toronto, Toronto, ON, Canada.
⁷ Memorial University, St. John's, NL, Canada.
⁸ Eastern Health Authority, St. John's, NL, Canada.
⁹ Dalhousie University, Halifax, NS, Canada.
¹⁰ McGill University, Montréal, QC, Canada.
¹¹ Jewish General Hospital, Montréal, QC, Canada.
¹² BC Cancer, Vancouver, BC, Canada.
¹³ University of British Columbia, Vancouver, BC, Canada.
¹⁴ Mount Sinai Hospital, Toronto, ON, Canada.
¹⁵ Ontario Institute for Cancer Research, Toronto, ON, Canada.
¹⁶ The Hospital for Sick Children, Toronto, ON, Canada.

PMID: 35385106
PMCID: PMC9075003
DOI: 10.1093/oncolo/oyac039

Abstract

Background: We explored health professionals' views on the utility of circulating tumor DNA (ctDNA) testing in hereditary cancer syndrome (HCS) management.

Materials and methods: A qualitative interpretive description study was conducted, using semi-structured interviews with professionals across Canada. Thematic analysis employing constant comparison was used for analysis. 2 investigators coded each transcript. Differences were reconciled through discussion and the codebook was modified as new codes and themes emerged from the data.

Results: Thirty-five professionals participated and included genetic counselors (n = 12), geneticists (n = 9), oncologists (n = 4), family doctors (n = 3), lab directors and scientists (n = 3), a health-system decision maker, a surgeon, a pathologist, and a nurse. Professionals described ctDNA as "transformative" and a "game-changer". However, they were divided on its use in HCS management, with some being optimistic (optimists) while others were hesitant (pessimists). Differences were driven by views on 3 factors: (1) clinical utility, (2) ctDNA's role in cancer screening, and (3) ctDNA's invasiveness. Optimists anticipated ctDNA testing would have clinical utility for HCS patients, its role would be akin to a diagnostic test and would be less invasive than standard screening (eg imaging). Pessimistic participants felt ctDNA testing would add limited utility; it would effectively be another screening test in the pathway, likely triggering additional investigations downstream, thereby increasing invasiveness.

Conclusions: Providers anticipated ctDNA testing will transform early cancer detection for HCS families. However, the contrasting positions on ctDNA's role in the care pathway raise potential practice variations, highlighting a need to develop evidence to support clinical implementation and guidelines to standardize adoption.

Keywords: cancer detection; circulating tumor DNA; clinical utility; genomics; hereditary cancer syndromes.

PubMed Disclaimer

Figures

**Figure 1.**
Health professionals’ contrasting views on ctDNA’s utility in HCS management. Summary of health professionals views on ctDNA testing in HCS patients and the contrasting perspectives on 3 themes between optimists and pessimists.

See this image and copyright information in PMC

References

1. Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. . Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma. J Clin Oncol. 2019;37:1547-1557. 10.1200/JCO.18.02052 - DOI - PubMed
1. Tie J, Kinde I, Wang Y, et al. . Circulating tumor DNA as an early marker of therapeutic response in patients with metastatic colorectal cancer. Ann Oncol. 2015;26:1715-22. 10.1093/annonc/mdv177 - DOI - PMC - PubMed
1. Corcoran RB, Chabner BA.. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379:1754-1765. 10.1056/NEJMra1706174 - DOI - PubMed
1. Yong E. Cancer biomarkers: written in blood. Nature. 2014;511:524-6. 10.1038/511524a - DOI - PubMed
1. Remon J, Menis J, Hasan B, et al. . The apple trial: feasibility and activity of AZD9291 (Osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. EORTC 1613. Clin Lung Cancer. 2017;18:583-588. 10.1016/j.cllc.2017.02.005 - DOI - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

Collaborators

Affiliations

"Game Changer": Health Professionals' Views on the Clinical Utility of Circulating Tumor DNA Testing in Hereditary Cancer Syndrome Management

Authors

Collaborators

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Miscellaneous